Stereotaxis (NYSE: STXS) installed its Genesis Robotic Magnetic Navigation System at Klinikum Fürth in Fürth, Germany, making the hospital the first in the country to deploy the platform. The installation began on February 9 2026 and the system is already treating patients, marking a significant expansion into the European electrophysiology market.
The Genesis system is engineered for rapid, semi‑mobile deployment that requires minimal construction, enabling hospitals to adopt the technology quickly. By adding a German customer, Stereotaxis expands its installed base and gains early revenue from both the system sale and the recurring catheter usage that the platform generates. This milestone supports the company’s strategic shift toward a platform‑based business model that prioritizes high‑margin consumables alongside system sales.
Stereotaxis’s recent financials provide context for the importance of this win. In Q3 2025 the company reported revenue of $7.5 million, a 10.98% miss versus consensus, and an EPS of –$0.07 versus –$0.06. Management highlighted that the miss was driven by a temporary increase in marketing and sales expenses as the company accelerated its European rollout. The company now expects Q4 2025 revenue to exceed $9 million and is guiding 2026 revenue to surpass $10 million, underscoring the growth trajectory that the German installation helps to fuel.
CEO David Fischel said, “We are proud to partner with Klinikum Fürth to expand access to minimally invasive arrhythmia care in Germany. The Genesis platform’s rapid deployment and high‑precision navigation are already delivering clinical value, and this partnership demonstrates the scalability of our technology across diverse hospital environments.” His comments reinforce the company’s confidence in the platform’s market fit and its ability to generate recurring revenue streams.
Investors have reacted positively to Stereotaxis’s expanding European footprint and the growing share of recurring revenue. The company’s recent FDA approval of the MAGiC ablation catheter and the strong performance in Q1 2025 earnings—both of which drove market enthusiasm—provide a backdrop that amplifies the significance of the German launch.
The Klinikum Fürth installation positions Stereotaxis to capture a larger share of the European arrhythmia market, strengthens its competitive differentiation, and accelerates the company’s transition to a diversified, platform‑based model that balances system sales with high‑margin consumables.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.